retatrutide weight loss phase 2 trial results of a new medication, Retatrutide, showed the highest amount of in a clinical so far. 24% of body weight lost. An average of 58 pounds over 48 weeks! The medical management of Retatrutide Delivers Significant Hemoglobin A1C

Vehicle contained 5% Cremophor in saline

Sci Total Environ 318:143

PlexusDx focuses on precision assessment to support informed conversations with your healthcare provider

Our pharmacy can ship your medication to your home if you would like your medication dispensed through the Felix Pharmacy network

Indications and Usage Saxenda (liraglutide) injection 3 mg is indicated in combination with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60kg and obesity Adults with overweight in the presence of at least one weight related comorbid condition Limitations of Use Saxenda contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist The safety and effectiveness of Saxenda in pediatric patients with type 2 diabetes have not been established Important Safety Information for Saxenda WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice